MSB 3.76% $1.03 mesoblast limited

Real patient review on Mesoblast treatment

  1. 370 Posts.
    lightbulb Created with Sketch. 72
    As market tanked globally, I think it might be one of the better times to buy mesoblast, before its FDA decision.
    The inherent risk obviously is the outcome of FDA and the subsequent market traction of its product.

    However, give its market cap about $1.1bn AUD, with the advance of its technlogy (compared to its global peers) with three phase-three stem-cell treatment and a web of patents. I think it can potentially rival the status of CSL, as a global biotech firm.

    For the weekend, just want to share some light video material about patient review on Mesoblast treatment.
    Personally, I think its science and stem-cell treatments are absolutely solid and life-saving, especially for conditions, which conventional standard of care could not treat. It would be a loss to people, if its treatment does not get FDA and other approvals to benefit more patients globally.





    Last edited by eight: 08/03/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.03
Change
-0.040(3.76%)
Mkt cap ! $1.170B
Open High Low Value Volume
$1.07 $1.07 $1.01 $13.19M 12.81M

Buyers (Bids)

No. Vol. Price($)
3 61090 $1.02
 

Sellers (Offers)

Price($) Vol. No.
$1.03 239558 5
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.